Effects of IL-6 Administration inmpl−/− Mice
| . | mpl+/+ . | mpl−/− . | ||
|---|---|---|---|---|
| Carrier . | IL-6 . | Carrier . | IL-6 . | |
| Spleen weight (mg) | 106 ± 14 | 188 ± 25* | 128 ± 23 | 179 ± 38† |
| Platelets (×10−6/mL) | 758 ± 116 | 1,213 ± 170* | 48 ± 11 | 107 ± 28* |
| Hematocrit (%) | 46 ± 2 | 44 ± 3 | 46 ± 2 | 42 ± 2† |
| WCC (×10−6/mL) | 4.1 ± 0.3 | 4.7 ± 1.9 | 5.1 ± 1.1 | 4.5 ± 1.9 |
| Megakaryocytes | ||||
| Bone marrow (per 30 hpf) | 103 ± 8 | 169 ± 28* | 7.5 ± 3.0 | 17 ± 6‡ |
| Spleen (per 60 hpf) | 36 ± 26 | 72 ± 25 | 1.0 ± 1.0 | 3.5 ± 2.0‡ |
| Megakaryocyte progenitor cells | ||||
| Bone marrow (×10−3 per femur) | 10.9 ± 4.7 | 18.9 ± 3.3‡ | 2.2 ± 0.9 | 4.8 ± 1.2‡ |
| Spleen (×10−3) | 8.5 ± 4.3 | 48.7 ± 6.4* | 3.2 ± 1.4 | 8.6 ± 3.9* |
| . | mpl+/+ . | mpl−/− . | ||
|---|---|---|---|---|
| Carrier . | IL-6 . | Carrier . | IL-6 . | |
| Spleen weight (mg) | 106 ± 14 | 188 ± 25* | 128 ± 23 | 179 ± 38† |
| Platelets (×10−6/mL) | 758 ± 116 | 1,213 ± 170* | 48 ± 11 | 107 ± 28* |
| Hematocrit (%) | 46 ± 2 | 44 ± 3 | 46 ± 2 | 42 ± 2† |
| WCC (×10−6/mL) | 4.1 ± 0.3 | 4.7 ± 1.9 | 5.1 ± 1.1 | 4.5 ± 1.9 |
| Megakaryocytes | ||||
| Bone marrow (per 30 hpf) | 103 ± 8 | 169 ± 28* | 7.5 ± 3.0 | 17 ± 6‡ |
| Spleen (per 60 hpf) | 36 ± 26 | 72 ± 25 | 1.0 ± 1.0 | 3.5 ± 2.0‡ |
| Megakaryocyte progenitor cells | ||||
| Bone marrow (×10−3 per femur) | 10.9 ± 4.7 | 18.9 ± 3.3‡ | 2.2 ± 0.9 | 4.8 ± 1.2‡ |
| Spleen (×10−3) | 8.5 ± 4.3 | 48.7 ± 6.4* | 3.2 ± 1.4 | 8.6 ± 3.9* |
Mean ± standard deviation of data from 4 mice in each group. Progenitor cell numbers were enumerated from stained semisolid agar cultures containing IL-3, SCF, and EPO and incubated in 5% CO2 in air at 37°C for 7 days.
Abbreviation: hpf, high power field.
P < .01 for comparison with carrier-injected controls of the same phenotype.
P = .06.
P < .05.